A new consumer healthcare company
GSK’s Consumer Healthcare business is on track to become an independent company through a proposed demerger from GSK in mid-2022. The new business, to be named Haleon, is expected to be a world-leader in consumer healthcare, offering the prospect of attractive organic sales growth, operating margin expansion and consistent high cash generation.
Led by its purpose to deliver better everyday health with humanity, it will be strongly positioned to play a vital role in a growing sector that is more relevant than ever. Haleon will have a world-class portfolio of category-leading global brands, including Sensodyne, Voltaren, Panadol and Centrum, brands that are trusted by healthcare professionals, customers and people worldwide to improve the health and wellbeing of individuals and their communities.
FAQs for shareholders
GSK announces appointments to Designate Haleon Board
On 15 March 2022 we announced the appointment of six directors to the designate Board of Haleon. The new appointments follow Sir Dave Lewis’s appointment as Chair Designate in December 2021 – who has led this search and selection process – and represent further progress to create a new, qualified Board for Haleon with the appropriate mix of skills, experience, diversity, and continuity. Read the press release for full details.
Consumer Healthcare Capital Markets Day
GSK's Consumer Healthcare Capital Markets Day took place on Monday 28 February 2022. This event provided details on our strategy, brands, capabilities and operations, as well as detailed financial information and future growth ambitions ahead of the proposed listing on the London Stock Exchange following the anticipated demerger from GSK mid-2022.
GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company
Designate Executive Leadership Team
GSK announces appointments to Designate Haleon Board. Demerger and listing of Haleon expected in July 2022.
GSK introduces Haleon to investors. Global leader in consumer health set to be a newly independent company
Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands
Redburn CEO conference 2021- Brian McNamara (01 December 2021)
Brian McNamara, CEO of GSK Consumer Healthcare participated virtually in the 2021 Redburn CEO Conference. He provided an overview of our business and broader industry.
Exane BNP Paribas 23rd European CEO Conference – Brian McNamara (10 June 2021)
Brian McNamara, CEO, GSK Consumer Healthcare, presented at the conference and provided an introduction to GSK Consumer Healthcare and outlined our purpose, strategy, category-leading brands and capabilities, as well as an overview of the consumer healthcare sector.
Click here to download slides
Global Headquarters (London, UK)
VP, Global Corporate Media Relations
Director, Global Corporate Media Relations, Pharmaceuticals
Director, Global Corporate Media Relations, Vaccines and Global Public Health
VP, Global Product & Pipeline Communications & US Corporate Communications
Head, US Corporate Communications
You may be interested in
Haleon will continue to use and protect your personal information in accordance with the same notices and practices in effect prior to our divestiture from GSK. The GSK Privacy Notice explains how we collect, use, share and protect your personal information, as well as how you can exercise your rights in regard to your personal information. Upon divestiture, Haleon will update the Privacy Notice to identify the new company (“Haleon”) and to let you know how to reach the new company with questions or requests related to your personal information.